

FOR IMMEDIATE RELEASE

January 16, 2017

Eisai Co., Ltd.
Chugai Pharmaceutical Co., Ltd.

**TRANSFER OF RIGHTS TO INSOMNIA TREATMENT / ANAESTHESIA INDUCTION AGENT
FLUNITRAZEPAM IN JAPAN**

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Chugai Pharmaceutical Co., Ltd. (Headquarters: Tokyo, Chairman & CEO: Osamu Nagayama, "Chugai") announced today that Eisai's acquisition of the rights for manufacturing active pharmaceutical ingredients (API) for Japan from F. Hoffman-La Roche Ltd. (Headquarters: Basel, Switzerland, CEO: Severin Schwan, "Roche") for the insomnia treatment / anaesthesia induction agent flunitrazepam (Eisai product name: Silece[®], Chugai product name: Rohypnol[®]) as well as the marketing authorization held by Chugai for Rohypnol in Japan has been agreed upon by the three companies, and this contract has come into effect.

Under this agreement, Eisai acquires the rights to manufacture API as well as intellectual property for

<Notes to editors>

1. About Rohypnol® (flunitrazepam)

1) Insomnia treatment Rohypnol® Tablet 1, Rohypnol® Tablet 2

[Indications for use]

Insomnia, preanaes

